Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (24)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  2. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

    Journal for immunotherapy of cancer, Vol. 12, Núm. 7

2023

  1. Serum levels of S-100 protein are directly proportional to the size, number, thickness and degree of cellularity of congenital melanocytic nevi

    Journal of the American Academy of Dermatology, Vol. 89, Núm. 5, pp. 1074-1077

2022

  1. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

  2. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

  3. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2015

  1. Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression

    Gene Therapy, Vol. 22, Núm. 11, pp. 856-865

  2. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer

    Human Gene Therapy, Vol. 23, Núm. 12, pp. 1258-1268

2011

  1. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

  2. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

  3. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

2010

  1. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 11, pp. 1621-1631

  2. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells

    European Journal of Immunology, Vol. 40, Núm. 12, pp. 3389-3402

  3. Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo

    Gene Therapy

  4. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

  2. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

  3. PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector

    Gene Therapy, Vol. 16, Núm. 1, pp. 136-141